beta
How it worksFor specialistsKnowledgeBlogFAQ
Sign in
NutriFit®

Product

Knowledge baseBlogRecipesOur pricingNutriFit calculatorsMCP Server

Documents

Privacy policyUser agreementPublic offer

Help

Support
© 2026 NutriFit. All rights reserved.V1.0.2348 · 2025–2026

Dietary fibre and microbiota

Categories
Knowledge · Nutrition

Psyllium: Gut, LDL, Dosage, and Safe Use

How Plantago ovata husk retains water, alters stool consistency, and participates in bile acid metabolism. We analyze human studies on constipation, IBS, LDL, glucose, and satiety, distinguishing clinical results from laboratory mechanisms. We explain dosing, gradual introduction, drug interactions, and safety guidelines.

September 2, 2026
Knowledge · Nutrition

Fermented Foods: Microbiota, Digestion, and Safety

Fermentation alters the food matrix, but its effects depend on the product, cultures, and processing. We break down the confirmed mechanism of lactose digestion and human studies on the microbiota, immune markers, blood pressure, and glucose. We also explain histamine, medication interactions, pasteurization, and portion choices.

September 2, 2026
Knowledge · Nutrition

Resistant Starch: Effects of Cooling, Microbiota, and Dosage

A portion of starch passes through the small intestine without full digestion, acting as a substrate for the microbiota. We analyze types of resistance, rice cooling, metabolic studies, Lynch syndrome, actual dosages, and safe practices.

September 2, 2026
Knowledge · Nutrition

Dietary Fiber and Prebiotics: Properties, Effects, and Tolerance

Solubility, viscosity, and fermentability are distinct fiber properties. We explore the WHO guidelines, human trials on psyllium, beta-glucan, and inulin, criteria for prebiotics, and safe methods for increasing dietary intake.

September 2, 2026
Knowledge · Nutrition

Probiotics: Strains, Clinical Effects, and Safety

Probiotics are chosen based on specific strains, composition, dosage, and clinical objectives. We analyze interactions with the gut environment, positive and negative human trials, AGA recommendations, and risks in cases of severe illness, immunodeficiency, and central catheters.

September 2, 2026